Application of Bone Marrow Mesenchymal Stem Cells Effectively Eliminates Endotoxemia to Protect Rat from Acute Liver Failure Induced by Thioacetamide

Ting Jiang1 · Geng Xia1 · Bo Yang1 · Hong-wei Zhang2 · Yue-shan Yin1 · Cheng-wei Tang3 · Jin-hui Yang1

Received: 2 October 2021 / Revised: 29 November 2021 / Accepted: 14 December 2021 / Published online: 5 February 2022
© The Author(s) 2022

Abstract
BACKGROUND: Endotoxemia is related to worse clinical outcomes in acute liver failure (ALF), but its management remains unsatisfactory. In this study, we aimed to assess whether the application of bone marrow mesenchymal stem cells (BMSCs) could eliminate endotoxemia and protect rats against ALF induced by thioacetamide (TAA).

METHODS: BMSCs were isolated from rats and identified by the specific morphology, differentiation potential, and surface markers. The optimal dose of TAA for this study was explored and TAA-induced ALF rats were randomized to three groups: the normal control group (Saline), ALF group (TAA + Saline), and BMSCs-treated group (TAA + BMSCs). The intestinal migration and differentiation of BMSCs was tracked in vivo, and intestinal permeability, endotoxin and inflammatory cytokines, histology, and mortality were analyzed. Moreover, we added the inhibitor of the PI3K/AKT/mTOR signaling pathway into the co-culture system of BMSCs with enterocytes and then performed CK and Villin expression experiments to assess the role of PI3K/AKT/mTOR signal pathway in the intestinal differentiation of BMSCs.

RESULTS: BMSCs migrated to the intestinal injury sites and differentiated into enterocytes, intestinal permeability was decreased compared with the ALF group. The higher expression of endotoxin and inflammatory cytokines were reversed after BMSCs transplantation in rats with ALF. Mortality and intestinal lesion were significantly decreased. Blocking the PI3K/AKT/mTOR signal pathway inhibited BMSCs’ intestinal differentiation in vitro.

CONCLUSION: BMSCs can eliminate endotoxemia and reduce mortality in rats with ALF, and the PI3K/AKT/mTOR signal pathway is involved in intestinal differentiation. BMSCs transplantation could be a potential candidate for the treatment of endotoxemia in ALF.

Keywords Bone marrow mesenchymal stem cells · Acute liver failure · Endotoxemia · Differentiation · PI3K

1 Introduction

Acute liver failure (ALF) is characterized by a sudden development of liver dysfunction and rapid hepatocellular necrosis, may progress to hepatic coma even death due to various etiologies, including drug toxicity, hepatic ischemia, immune-mediated attack, and viral hepatitis such as hepatitis B and hepatitis C [1, 2]. Endotoxemia represents the severe stage of ALF and is associated with mortality and heavy economic and social burden [3]. Reasons for endotoxemia in ALF include intestinal and hepatic factors, which also interact with each other [4]. Although liver
transplantation is considered a curative treatment, the disparity between demand and supply and severe postoperative complications limit the applicability [5, 6]. Therefore, prevention and treatment of endotoxemia are particularly important in ALF clinical practices.

Endotoxin is mainly produced by gram-negative bacteria which overgrow in the disordered intestinal environment. The disordered intestinal environment in ALF is usually associated with liver dysfunction, congestion of portal vein, and growth of pathogenic microorganisms [7]. First and foremost, severe liver dysfunction can result in the accumulation of toxic metabolites in circulation, such as putrescine, histamine, spermine, and spermidine, which are not only harmful to brain cells called the hepatic coma, but also a great challenge to enterocytes. A recent study shows that spermine and spermidine have a dose-dependent cytotoxic effect on intestinal cells grown in culture [8]. It has been reported that histamine was toxic for HT29 intestinal cells and induced cell apoptosis in a comparative analysis [9]. These data strongly suggest that liver function is essential to maintain a healthy intestinal environment. Meanwhile, the increased portal vein pressure caused by liver failure leads to intestinal congestion, which enhances the concentrations of toxic metabolites in the gut and causes intestinal mucosal barrier injury. Furthermore, the gut barrier damage could promote intestinal bacteria-endotoxin translocation and endotoxemia, which can increase the severity of the liver disease. Obviously, it is a vicious circle between liver and gut, the high mortality will be the last result. The effective treatment and prevention of endotoxemia can break the vicious circle.

Mesenchymal stem cells (MSCs) attract a lot of attention owing to the excellent ability of self-renewal and differentiation into various tissues. Furthermore, compared with embryonic (ESCs) and induced pluripotent stem cells (iPSCs), MSCs are easily isolated from bone marrow called the bone marrow mesenchymal stem cells (BMSCs) and characterized without the limitation of ethical problems, the way of cell retention and immunological rejection [10, 11]. Recent studies have described the applications of BMSCs for liver diseases. BMSCs could migrate to the injured liver and regenerate in the mice receiving partial hepatectomy (PH) and even improve the alleviation of liver fibrosis [12–14]. Moreover, the application of BMSCs has demonstrated the potential for the alleviation of liver injury and inflammation by inhibiting the activation of inflammatory factors [15, 16]. However, studies on BMSCs therapy for endotoxemia in ALF were scarce.

The potential of BMSCs therapy largely depends on their migration, proliferation, and differentiation, regulated by multiple signaling pathways and factors, including the Wnt signal transduction pathway, oxidative stress, transforming growth factor beta (TGF-β) pathway, and phosphoinositide kinase-3 (PI3K)/protein kinase B (AKT) signal pathway [17–20]. Among them, the classical PI3K/AKT signaling pathway is crucial, affecting the migration, proliferation, and intestinal differentiation of BMSCs [21]. The activated AKT initiates downstream mammalian target of rapamycin (mTOR)/p70 S6K1 signaling resulting in the expression of genes that control protein synthesis, cell growth, and proliferation [22]. Therefore, we speculate that the PI3K/AKT/mTOR signaling pathway may induce intestinal differentiation and trigger downstream target genes.

In this study, we aimed to explore the effects of BMSCs on ALF rats by repairing the intestinal mucosal barrier and eliminating endotoxemia. Moreover, we used LY294002 to inhibit the PI3K/AKT/mTOR signal pathway in vitro and then observed the changes in intestinal differentiation of BMSCs.

2 Materials and methods

2.1 Preparation of rat BMSCs

2.1.1 Isolation of rat BMSCs

BMSCs were isolated from SD rats (half male and female, 6–8 weeks old, 200 ± 10 g) obtained from the experimental animal center of Kunming Medical University as described previously [23]. BMSCs were maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; cat. RNBJ9730; Sigma-Aldrich, St. Louis, MO, USA) containing 15% fetal bovine serum (FBS; Cat. 10,099,141; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml penicillin and 100 μg/ml streptomycin (Cat. SV30010; Hyclone, Thermo Fisher Scientific, Inc., Logan, UT, USA) in a humidified incubator maintained at 37 °C under 5% CO₂.

2.1.2 In vitro adipogenic differentiation and oil red O staining

The cells used for adipogenic differentiation were cultured with the adipogenic medium (Cat. 70,811; Saiye Bio, Guangzhou, China) for 16 days. Then, cells were stained with oil red O (Cat. 91,412; Saiye Bio). In brief, cells were washed with phosphate buffer saline (PBS; Cat. SH30256.02; Hyclone, Thermo Fisher Scientific, Inc.) and fixed with 4% paraformaldehyde (Cat. 51,829; Saiye Bio) for 30 min. After washing with PBS three times, cells were incubated with oil red O working solution for 30 min. Red color lipid droplets could be checked microscopically.
2.1.3 Flow cytometry

Cells harvested from SD rats were collected, centrifuged, counted, and adjusted to 1 × 10^6 cells/ml/tube. Cells were washed by PBS twice and resuspended in 100 μl PBS, then incubated with anti-CD34 (Cat. no. sc-7324; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-CD45 (Cat. no. 202207; Biolegend, San Diego, CA, USA), anti-CD90 (Cat. no. 202526; Biolegend) and anti-CD29 (Cat. no. ab36219; Abcam, Cambridge, UK) antibodies at room temperature in dark for half an hour. A FACS flow cytometer (CytoFLEX; Beckman Coulter, Inc., Brea, CA, USA) was used.

2.1.4 Cell cycle assays

Cells were washed twice with cold PBS and made into a 1 × 10^6/ml single-cell suspension, fixed with cold 70% ethanol at 4 °C overnight. After washing with 1 ml PBS once, cells were incubated with 500 μl PBS containing 50 μg/ml propidium iodide (PI; Cat. ab14083; Abcam), 100 μg/ml RNase A (Cat. 9001-99-4; Sigma-Aldrich), and 0.2% Triton X-100 (Cat. 9002-93-1; Solarbio Life Science, Beijing, China) at 4 °C in dark for 30 min and analyzed using a flow cytometer.

2.2 In vivo study

2.2.1 The ALF rat models and the application of BMSCs

In this study, ALF was induced by thioacetamide (TAA; Cat. no. HY-N1131, MedChemExpress, Shanghai, China) as previously described [24–26]. All rats (half male and female, 6–8 weeks old, 200 ± 10 g) were maintained under a specific pathogen-free condition with a 12-h light/dark cycle and free access to food and tap water at the Animal Facilities of the Kunming Medical University. To get an optimal animal model for this study, we divided the rats into groups to explore the best TAA dose. The rats were randomly allocated to 4 groups (n = 25 each group). Group 1 (control group) received saline via gavage for two days, and group 2–4 (ALF groups) received different doses (200 mg, 300 mg, 400 mg/Kg/day; 2 days) of TAA via gavage. Then, after confirming the appropriate dose of TAA, we explored the therapeutic effect of BMSCs on rats with ALF. Rats were divided into 3 groups (n = 20 each group): saline (gavage/caudal vein), TAA (gavage) + saline (caudal vein), and TAA (gavage) + BMSCs (1 × 10^6 cells, caudal vein). All rats were sacrificed by CO₂ asphyxiation for examinations.

2.2.2 Histology

Samples (livers and intestines) from rats were fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Sections (4 μm) were stained with hematoxylin and eosin (H&E; Cat. 57,390; Saiye Bio). Images (× 100 magnification) were taken from each sample, and histopathological evaluation of the entire section was performed in a blinded manner. The injury of livers and intestines was scored using the modified histopathologic score described previously [27–29]. These criteria for the histological score were shown in Table 1.

2.2.3 In vivo assessment of intestinal barrier permeability

Animals were gavaged with FITC-labeled dextran (6 mg/100 g body weight; Cat. 60,842-46-8, Sigma). Food and water were withdrawn 4 h before the FITC-labeled dextran gavage. Then plasma was collected 4 h after gavage. The fluorescence intensity of the plasma was measured using a plate reader (Cytation1; Biotek, Winskys, VT, USA). The FITC-labeled dextran concentrations in plasma were determined by the standard curve.

### Table 1 Histological criteria for the assessment of liver and intestine damage

| Score | Liver | Intestine |
|-------|-------|-----------|
| 0     | No damage | No damage |
| 1     | Minimal congestion and vacuolization, single-cell necrosis | Mild focal epithelial edema and necrosis |
| 2     | Mild congestion and vacuolization, < 30% necrosis | Moderate diffuse swelling and necrosis of the villi |
| 3     | Moderate congestion and vacuolization, 30–60% necrosis | Severe necrosis with evidence of neutrophil infiltration in the submucosa |
| 4     | Severe congestion and vacuolization, > 60% necrosis | Major widespread necrosis with massive neutrophil infiltration and evidence of hemorrhage |
2.2.4 RNA isolation and quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

Total RNA was isolated from the intestinal tissues using the RNAiso kit (Cat. 9109; TaKaRa, Kyoto, Japan), according to the manufacturer’s protocol. cDNA was generated using the HiScript II 1st Strand cDNA Synthesis Kit (Cat. R211-01; Vazyme Biotech Co., Nanjing, China). Primers were listed in Table 2 and ChamQTM Universal SYBR qPCR master mix was obtained from the company (Cat. Q711-02; Vazyme Biotech Co.). Gene expression was calculated relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

2.2.5 Tracking BMSCs in vivo

BMSCs were incubated with BrdU labeled solution (final concentration 10 μmol/L; Cat. no. 6813, Cell Signaling Technology, Inc., Boston, MA USA) for 48 h and then washed five times with serum-free DMEM medium, digested with 0.25% trypsin (Cat. T4049; Sigma-Aldrich), and made a cell suspension (1 × 10^7/ml) for transplantation. The intestines of rats were obtained and fixed in 4% paraformaldehyde and embedded in paraffin. Sections were cut using a standard procedure for immunofluorescence staining (Cat. no. 4408/2369/4414; Cell Signaling Technology, Inc.). BMSCs cells (BrdU+ cells) and intestinal cells differentiated from BMSCs (BrdU+Villin+ cells) in intestinal mucosa could be observed under the microscope.

2.2.6 Determination of diamine oxidase (DAO) and endotoxin

The concentration of DAO in plasma was measured using a commercial kit (Cat. no. ab241004; Abcam) according to the manufacturer’s instructions. The DAO activity could be measured when plasma was incubated with enzyme mix for 1 h at 37 °C. The endotoxin in plasma was assayed by the endotoxin kit (Cat. no. A39552; Thermo Fisher Scientific, Inc.).

2.2.7 Enzyme-linked immunosorbent assay (ELISA)

The levels of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) in serum were determined according to the manufacturer’s instructions of the ELISA kits (IL-6; Cat. no. BMS625; Thermo Fisher Scientific, Inc.) (TNF-α; Cat. no. KRC3011; Thermo Fisher Scientific, Inc.).

2.3 Intestinal differentiation and transwell co-culture system

Transwell co-culture system (Cat. PIEP30R48; Merck Millipore, Darmstadt, Hesse-Darmstadt, Germany) was used for intestinal differentiation of BMSCs in vitro. Briefly, the lower chamber was loaded with BMSCs (1 × 10^6 cells/well) and the upper insert was loaded with epithelial cells of the small intestinal crypt in rats (IEC-6; 1 × 10^6 cells/well) which were obtained from Kunming Cell Bank of Chinese Academy of Sciences (Cat. no. KCB200720YJ). The induction system was placed in an incubator with 5% CO2 at 37 °C for 10 days. To inhibit the PI3K/AKT/mTOR signaling pathway, the inhibitor LY294002 (20 μM; Cat. no. ab120243; Abcam) was added to the co-culture system on the first day.

2.4 Immunofluorescence

Cells were fixed with PBS containing 4% paraformaldehyde and embedded in paraffin. Sections were cut taking a standard procedure for immunofluorescence staining (Cat. no. 4408/2369/4414; Cell Signaling Technology, Inc.). BMSCs cells (BrdU+ cells) and intestinal cells differentiated from BMSCs (BrdU+Villin+ cells) in intestinal mucosa could be observed under the microscope.

| Table 2 | Forward and reverse primers sequences of genes |
|---------|-----------------------------------------------|
| Gene    | Forward primers sequences (5’-3’) | Reverse primers sequences (5’-3’) |
| Occludin| TGAAAGTCCACCTCCTATCGAGA               | CCGGATAAAAGGATCGCTGGG           |
| JAM A   | GGCAAGGTTGCTGGTGACA                 | GGCACTTGGACAGTTGCTTTCG   |
| GAPDH   | CCTTCATGACCTCAACTCATG               | CTCTCCATGTTGGGAGAGAC         |

JAM A= junctional adhesion molecule A, GAPDH= glyceraldehyde-3-phosphate dehydrogenase
blocked for 1 h at room temperature with 5% nonfat dried milk. After washing in tris-buffered saline Tween-20 (TBST; Cat. no.56711; Saiye Bio), the membranes were immunoblotted with the following antibodies: anti-IL-6, anti-TNF-α, anti-AKT, anti-mTOR, anti-CK, anti-Villin, anti-β actin (Cat. no. ab9770/ab66579/ab8805/ab32028/ab115293/ab109516/ab8227; Abcam). The blots were then incubated with the corresponding horseradish peroxidase-conjugated IgG (Cat. no. ab7090 and ab7125; Abcam), and the signals were detected using a chemiluminescence reagent.

2.6 Statistical analysis

Data are presented as mean ± standard deviation (SD). Differences between groups were analyzed by Student t-test or Mann–Whitney U test when appropriate. Survival analyses were described by Kaplan–Meier method and compared by the Log-rank test. The data were processed using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) and SPSS 23.0 (IBM Corp., Armonk, NY, USA). A p value of < 0.05 was considered statistically significant.

3 Results

3.1 Identification of BMSCs from rats

The bone marrow of SD rats was used for isolation of the BMSCs. When the cells were cultured to the third passage, most of the cells were arranged in a whirlpool type and adhered to the wall of dishes, the shape of the cells was typically fibroblast-like or spindle-shaped (Fig. 1A). To demonstrate the pluripotency of the isolated cells, we induced adipogenic differentiation. Oil red O staining showed that droplets of fat were in the cells after the adipogenic induction compared with the control group (Fig. 1B). The specific surface markers of stem cells were detected by flow cytometry. We could notice the high expressions of CD90 (79.14%) and CD29 (98.27%) but low levels of CD45 (5.83%) and CD34 (0.05%) (Fig. 1). Taken together, these isolated cells could be identified as BMSCs. In addition, to ensure the follow-up experiments, we tested the cell cycle of BMSCs. As shown in Fig. 1C, these cells were in a state with a good ability for proliferation, that meets our experimental requirements.

3.2 Effects of different doses of TAA on rats for ALF

Intestine lesions based on the ALF and appropriate survival rate were two bases for this study. To get an optimal ALF animal model, we divided the rats into four groups to explore the effects of different doses of TAA (Fig. 2). Both the group of TAA 300 mg/Kg/day and the group of TAA 400 mg/Kg/day showed typical hepatocenteropathology of ALF (Fig. 2C, D), while the group of TAA 400 mg/Kg/day had higher mortality (Fig. 2B), which was difficult to guarantee the follow-up experiments. Therefore, for this study, the dosage of TAA 300 mg/Kg/day was adopted.

3.3 BMSCs migrated to the site of the injured intestine and affected intestinal permeability

The general experimental procedure of this animal study is shown in Fig. 3A. About 72–96 h after injection of the BrdU-labeled BMSCs, the results showed the transplanted BMSCs had migrated into the injured intestine and differentiated into enterocytes (BrdU+/Villin+ cells) (Fig. 3B). We next measured the consequence of BMSCs on intestinal permeability in vivo. BMSCs decreased intestinal permeability, as reflected by reduced plasma dextran concentrations (72 h, p = 0.02; 96 h, p = 0.01) (Fig. 3C). Consistently, these intestinal alterations were associated with higher mRNA expression of occludin (72 h, p = 0.01; 96 h, p = 0.008) and JAM A (96 h, p = 0.007) in the BMSCs-treated group (Fig. 3D, E). These results suggested that BMSCs migrated to the site of the injured intestine and differentiated into enterocytes, resulting in the reconstruction of the intestinal epithelial barrier.

3.4 The administration of BMSCs ameliorated endotoxemia and reduced the mortality of rats with TAA-induced ALF

When compared with TAA + saline animals, the endotoxemia from rats administrated with BMSCs has been greatly alleviated, as shown by reductions in both the endotoxin (72 h, p = 0.02; 96 h, p = 0.007) and the DAO (72 h, p = 0.03; 96 h, p = 0.008) in serum (Fig. 4A, B). As IL-6 and TNF-α were important proinflammatory cytokines in ALF, we measured the expressions after the administration of BMSCs. Significant decreases in serum IL-6 (96 h, p = 0.03) and TNF-α (96 h, p = 0.03) were observed after BMSCs transplantation (Fig. 4C, D). A trend for the decrease in intestinal proinflammatory cytokine was also noticed by western blot (Fig. 4E). BMSCs led to significant reductions in IL-6 (48 h, p = 0.02; 96 h, p = 0.007) and TNF-α (48 h, p = 0.04; 96 h, p = 0.006) in intestines (Fig. 4F, G). From the morphological point of view, when the rats were treated with BMSCs, the intestine architecture was well preserved and the intestine was completely prevented from the edema and necrosis induced by TAA (Fig. 4H). Moreover, total mortality was higher (p = 0.03) in TAA + saline rats (12 of 25 deaths, 48%
mortality) than in TAA + BMSCS rats (4 of 25 deaths, 16% mortality), the administration of BMSCs reduced mortality among ALF rats (Fig. 4I).

3.5 PI3K/AKT/mTOR signal pathway was involved in the intestinal differentiation of BMSCS in vitro

The above results in this study showed that BMSCs could migrate to the intestinal injury sites and differentiate into enterocytes, resulting in the reconstruction of the intestinal epithelial barrier and following reductions of endotoxin and mortality. Furthermore, we performed the transwell coculture system to investigate whether the PI3K/AKT/mTOR signaling pathway is associated with the intestinal differentiation of BMSCS. Our results showed that the spindle-shaped BMSCs morphology changed to a polygonal, round-like IEC-6 morphology after the co-culture (Fig. 5). In addition, CK and Villin, two specific molecules of enterocytes, were found to be highly expressed in BMSCs which were co cultured with IEC-6 (Fig. 5B, D). Statistical analysis showed that after a 10-day co-culture, the levels of CK and Villin in BMSCs with IEC-6 were more than those in BMSCs without IEC-6 (Fig. 5C, E). Furthermore, the effect of the PI3K/AKT/mTOR signaling pathway in BMSCs intestinal differentiation was investigated by western blot (Fig. 5F). The results showed significant decreases in CK and Villin in the LY294002 group.
A) BrdU labeled solution (10μmol/L) is injected into mice, followed by gavage with TAA (300mg/Kg) after 12 hours. BMSCs are used for injection. For assessment of intestinal barrier permeability, DAO, endotoxin, IL-6, TNF-α.

B) Immunofluorescence images show the progression over time (24h, 48h, 72h, 96h).

C) Graphs showing changes in FITC detected in serum over time.

D) Graphs showing changes in Ocludin/GAPDH expression over time.

E) Graphs showing changes in JAM A/GAPDH expression over time.
compared with the control groups (Fig. 5G–J). These data suggested that the PI3K/AKT/mTOR signaling pathway was involved in the intestinal differentiation of BMSCs in vitro.

Fig. 3 Intestinal migration of BMSCs and decreased intestinal permeability. A Flow chart of animal experiments. B Colocalization of EdU-labeled BMSCs and Villin was observed using immunofluorescence; DAPI-blue, BMSCs-BrdU-green; Villin-red Scale bars, 20 μm. C Fluorescence readings in plasma 4 h after gavage with FITC-dextran from groups. D, E Intestine mRNA levels of Occludin and JAM A; Values are normalized with GAPDH. ns \( p > 0.05 \), * \( p < 0.05 \), ** \( p < 0.01 \). TAA, thioacetamide; DAO, diamine oxidase; JAM A, junctional adhesion molecule A, GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Fig. 4 BMSCs administration eliminated endotoxemia and reduced mortality in the acute liver failure in vivo. A Endotoxin levels in serum. B DAO levels in serum. C IL-6 levels in serum. D TNF-α levels in serum. E IL-6 and TNF-α protein expressions in intestines measured by Western blotting. F and G The expressions of IL-6 and TNF-α decreased greatly in the BMSCs group than in the control group. H H&E staining of rat intestines; welling and necrosis of the villi were milder in the BMSCs group (black arrows); Scale bars 50 μm. I Survival analysis of groups; \( p = 0.03 \). ns \( p > 0.05 \), * \( p < 0.05 \), ** \( p < 0.01 \). TAA, thioacetamide; DAO, diamine oxidase; IL-6, interleukin-6; TNF-α, tumor necrosis factor-alpha.
The severe clinical outcomes of patients with ALF are closely related to the occurrence of hepatic coma, which is usually caused by endotoxemia. Indeed, endotoxemia is observed in 75–93.3% of ALF and severe hepatitis [31]. The common treatments such as antibiotics, artificial liver support systems, and nutritional support are still unsatisfactory [32]. Currently, with an inspiring development in stem cell technology, cell therapy has attracted a lot of interest in liver diseases. In an open-label randomized controlled study, the administration of allogeneic BMSCs reduced serum total bilirubin (TBIL) and model for end-stage liver disease (MELD) scores in 56 patients with acute-on-chronic liver failure (ACLF) [33]. Some studies proved that MSCs could differentiate into hepatocyte-like cells (HLCs) in vivo, considering as one of the mechanisms of MSCs in the treatment of liver failure [34, 35]. While some experiments have suggested that MSCs cannot differentiate into HLCs after engraving even if the administration can improve survival, reduce alanine aminotransferase (ALT), and relieve liver injury [36]. These findings demonstrate that the therapeutic mechanism of MSCs in liver failure is not just dependent on the liver engraving of exogenous stem cells and liver repairing.

It is worth mentioning that some inflammatory factors including IL-6, TNF-α, and CD8+ T cells, which are induced by bacteria and endotoxins (lipopolysaccharide, LPS) from the gut, are significantly decreased after the BMSCs application in liver failure [37]. Previous studies have indicated that the gut plays a significant role in endotoxemia based on liver failure. The level of plasma endotoxin in the colectomized rats had no difference from that in the control group, the contents of inflammatory factors and fatality were much lower in these ALF rats. Therefore, we investigated the role of BMSCs in the gut and endotoxemia while on ALF. The results suggested that the levels of plasma endotoxin and DAO were remarkably decreased in the BMSCs group compared to the TAA + saline groups. Also, the concentrations of IL-6 and TNF-α decreased markedly, resulting in an important increase in survival rate. Histology with intestines from groups showed that a better intestinal mucosal barrier was observed after the BMSCs application. Moreover, the levels of IL-6 and TNF-α in the intestine were strongly reduced in rats with BMSCs. These findings suggested that BMSCs were indeed effective in the treatment of ALF by eliminating endotoxemia and rebuilding the intestinal epithelial barrier.

The intestinal differentiation of BMSCs was thought to be involved in many therapeutic studies on intestinal diseases. A recent phase III randomized controlled trial showed fistula healing in patients with Crohn’s perianal fistulae treated via MSCs, and the reprogramming that allows MSCs to differentiate and migrate tissues was discussed [38]. Consequently, the animal experiment showed the activated inflammatory pathway in inflammatory bowel disease could be suppressed by stem cell transplantation to differentiate into intestinal epithelium [39]. In this study, we displayed the migration and intestinal differentiation of transplanted BMSCs in the injured intestinal tissues and the effects of intestinal repair, which was consistent with previous studies. We also carried out the co-culture system of BMSCs and IEC-6 in vitro using transwell and blocked the PI3K/AKT/mTOR signaling pathway. The data demonstrated that the blocking of the PI3K/AKT/mTOR signal pathway using LY294002 could inhibit intestinal differentiation, suggesting the PI3K/AKT/mTOR signal pathway may regulate intestinal differentiation and intestinal repair in ALF. However, the present study only investigated the PI3K/AKT signaling pathway in vitro. Further experiments in vivo are required to confirm the results of this study. Meanwhile, some previous studies have stated that the therapeutic effects of BMSCs were based on its released trophic and immunomodulatory factors such as TGF-β and interleukin 10 (IL-10) [40]. Also, BMSCs can inhibit cytotoxic CD8+ T lymphocyte (CTL) and NK cells through intercellular contact and paracrine factors including TGF-β and IL-10. Thus, we can not rule out the overlapping and non-differentiation effects of BMSCs in the present vivo study, further research is needed. Of note, the application of BMSCs is beneficial to the treatment and prevention of endotoxemia in ALF, and the intestinal differentiation of BMSCs contributed to the repair of the intestinal mucosal barrier.

In summary, we showed the therapeutic potential of BMSCs in ALF by repairing the intestinal epithelial barrier and preventing endotoxemia, and the PI3K/AKT/mTOR signaling pathway was involved in the intestinal differentiation of BMSCs. These data not only alarm us about the role of intestinal endotoxemia in ALF but also inspire us to build an effective cell therapy in the treatment of ALF.
Acknowledgement We thank The Talents Plan of Yunnan Science and Technology Commission of China (no. 2019IC034) for providing support for the study.

declarations

Conflict of interest The authors have no conflicts of interest to declare.

Ethical statement The study obeyed the laboratory animal welfare and ethic principle, and all the experimental animal procedures were carried out strictly following the protocol approved by the Animal Experimental Ethical Committee of Kunming Medical University (Approval number KMMU 2018020).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Stravitz RT, Lee WM. Acute liver failure. Lancet. 2019;394:869–81.
2. Thanapirom K, Treeprasertsuk S, Soonthornworsari N, Pooworawun K, Chaiteerakij R, Komolmit P, et al. The incidence, etiologies, outcomes, and predictors of mortality of acute liver failure in Thailand: a population-base study. BMC Gastroenterol. 2019;19:18.
3. Wang Z, Wang A, Gong Z, Biviano I, Liu H, Hu J. Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease. Clin Res Hepatol Gastroenterol. 2019;43:410–6.
4. Mancini A, Campagna F, Amodio P, Tuohy KM. Gut: liver: brain axis: the microbial challenge in the hepatic encephalopathy. Food Funct. 2018;9:1373–88.
5. Tan EX, Wang MX, Pang J, Lee GH. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. World J Gastroenterol. 2020;26:219–45.
6. Weiler N, Schlotmann A, Schnitzbauer AA, Zeuzem S, Welker MW. The epidemiology of acute liver failure: results of a population-based study including 25 million state-insured individuals. Dtsch Arztebl Int. 2020;117:43–50.
7. Wang XD, Ar’Rajah A, Andersson R, Soltesz V, Wang W, Svensson M, et al. The influence of surgically induced acute liver failure on the intestine in the rat. Scand J Gastroenterol. 1993;28:31–40.
8. Del Rio B, Redrueblo B, Linares DM, Ladero V, Ruas-Madiedo P, Fernandez M, et al. Spermine and spermidine are cytotoxic towards intestinal cell cultures, but are they a health hazard at concentrations found in foods? Food Chem. 2018;269:321–6.
9. Linares DM, del Rio B, Redrueblo B, Ladero V, Martin MC, Fernandez M, et al. Comparative analysis of the in vitro cytotoxicity of the dietary biogenic amines tyramine and histamine. Food Chem. 2016;197:658–63.
10. Both SK, van Apeldoorn AA, Jukes JM, Englund MC, Hyllner J, van Blitterswijk CA, et al. Differential bone-forming capacity of osteogenic cells from either embryonic stem cells or bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med. 2011;5:180–90.
11. Wang L, Zhu M, Guo Q, Fan X, Lu Y, Zhu S, et al. Comparing the reprogramming efficiency of mouse embryonic fibroblasts, mouse bone marrow mesenchymal stem cells and bone marrow mononuclear cells to iPSCs. In Vitro Cell Dev Biol Anim. 2012;48:236–43.
12. Danilova IG, Yushkov BG, Kazakova IA, Belousova AV, Minin AS, Abidov MT. Recruitment of macrophages and bone marrow stem cells to regenerating liver promoted by sodium phthalhydrazide in mice. Biomed Pharmacother. 2019;110:594–601.
13. Temnov AA, Rogov KA, Skilfas AN, Klychnikova EV, Hartl M, Djinovic-Carugo K, et al. Protective properties of the cultured stem cell proteome studied in an animal model of acetaminophen-induced acute liver failure. Mol Biol Rep. 2019;46:3101–12.
14. Sun T, Li H, Bai Y, Bai M, Gao F, Yu J, et al. Ultrasound-targeted microbubble destruction optimized HGF-overexpressing bone marrow stem cells to repair fibrotic liver in rats. Stem Cell Res Ther. 2020;11:145.
15. El-Sayed M, El-Feky MA, El-Amir MI, Hasan AS, Tag-Adeen M, Urata Y, et al. Immunomodulatory effect of mesenchymal stem cells: cell origin and cell quality variations. Mol Biol Rep. 2019;46:1157–65.
16. Wan YM, Li ZQ, Zhou Q, Liu C, Wang MJ, Wu HX, et al. Mesenchymal stem cells alleviated liver injury induced by chronic-binge ethanol feeding in mice via release of TGFβ6 and suppression of STAT3 activation. Stem Cell Res Ther. 2020;11:24.
17. Bae YK, Kim GH, Kwon JH, Kim M, Choi SJ, Oh W, et al. Primary cilia mediate Wnt5a/β-catenin signaling to regulate adipogenic differentiation of human umbilical cord blood-derived mesenchymal stem cells following calcium induction. Tissue Eng Regen Med. 2020;17:193–202.
18. Yang Y, Sun Y, Mao WW, Zhang H, Ni B, Jiang L. Oxidative stress induces downregulation of TP53IP2 and suppresses osteogenic differentiation of BMSCs during osteoporosis through the autophagy degradation pathway. Free Radic Biol Med. 2021;166:226–37.
19. Yang X, Chen Z, Chen C, Han C, Zhou Y, Li X, et al. Bleomycin induces fibrotic transformation of bone marrow stromal cells to treat height loss of intervertebral disc through the TGFBR1/Smad3 pathway. Stem Cell Res Ther. 2021;12:34.
20. Wang Q, Zhang N, Hu L, Xi Y, Mi W, Ma Y. Integrin β1 in adipose-derived stem cells accelerates wound healing via activating PI3K/PI4K pathway. Tissue Eng Regen Med. 2020;17:183–92.
21. Watanabe S, Arimura Y, Nagaishi K, Isshiki H, Onodera K, Nasuno M, et al. Conditioned mesenchymal stem cells produce pleiotropic gut trophic factors. J Gastroenterol. 2014;49:270–82.
22. Leppäniemi H, Halazonetis TD. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009;28:3067–73.
23. Jiang T, Shi ML, Xia G, Yang YN, Xu JM, Lei YJ, et al. Bone marrow mesenchymal stem cells differentiate into intestinal epithelial cells through the ERK1/2 pathway. Turk J Gastroenterol. 2019;31:459–65.
24. Demirel U, Yalniz M, Aygün C, Orhan C, Tuzcu M, Sahin K, et al. Allopurinol ameliorates thioacetamide-induced acute liver failure by regulating cellular redox-sensitive transcription factors in rats. Inflammation. 2012;35:1549–57.
25. Milewski K, Hilger W, Frąska I, Polowy R, Podsiadłowska A, Żołocinska E, et al. Carnosine reduces oxidative stress and reverses attenuation of righting and postural reflexes in rats with...
thioacetamide-induced liver failure. Neurochem Res. 2016;41:376–84.
26. Jiao FZ, Wang Y, Zhang WB, Zhang HY, Chen Q, Shi CX, et al. Protective role of AGK2 on thioacetamide-induced acute liver failure in mice. Life Sci. 2019;230:68–75.
27. Song HY, Sik Kim W, Kim JM, Bak DH, Moo Han J, Lim ST, et al. A hydroxyethyl derivative of chrysir exhibs anti-inflamatory activity in dendritic cells and protective effects against dextran sodium salt-induced colitis in mice. Int Immunopharmacol. 2019;77:105958.
28. Chen C, Liu YH, Cheng SB, Wu SL, Zhai XJ. The hepatoprotective effects of XCHD and MgIG against methotrexate-induced liver injury and inflammation in rats through suppressing the activation of AIM2 inflamasomes. Pathol Res Pract. 2020;216:152875.
29. Yang NN, Ye Y, Tian ZX, Ma SM, Zheng Y, Huang J, et al. Effects of electroacupuncture on the intestinal motility and local inflammation are modulated by acupoint selection and stimulation frequency in postoperative ileus mice. Neurogastroenterol Motil. 2020;32:e13808.
30. Han Y, Yu W, Zhang W, Yang Y, Walsh T, Oakeshott JG, et al. Variation in P450-mediated fenvalerate resistance levels is not correlated with CYP337B3 genotype in Chinese populations of Helicoverpa armigera. Pestic Biochem Physiol. 2015;121:129–35.
31. Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol. 2002;8:961–5.
32. Amadio P. Hepatic encephalopathy: diagnosis and management. Liver Int. 2018;38:966–75.
33. Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatology. 2017;66:209–19.
34. Yang JF, Cao HC, Pan QL, Yu I, Li J, Li LJ. Mesenchymal stem cells from the human umbilical cord ameliorate fulminant hepatic failure and increase survival in mice. Hepatobiliary Pancreat Dis Int. 2015;14:186–93.
35. Liu S, Guo R, Hou X, Zhang Y, Jiang X, Wang T, et al. Adipose-tissue derived porcine mesenchymal stem cells efficiently ameliorate CCl4-induced acute liver failure in mice. Cytotechnology. 2020;72:327–41.
36. Chen G, Jin Y, Shi X, Qiu Y, Zhang Y, Cheng M, et al. Adipose-derived stem cell-based treatment for acute liver failure. Stem Cell Res Ther. 2015;6:40.
37. Fang X, Liu L, Dong J, Zhang J, Song H, Song Y, et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B-induced decompensated liver cirrhosis. J Gastroenterol Hepatol. 2018;33:774–80.
38. Franco DL, Holubar SD, Lightner AL, Lashner BA, Shen B. Local stem cell therapy for Crohn’s perianal fistulae. Inflamm Bowel Dis. 2019;25:816-9.
39. Xing Y, Chen X, Cao Y, Huang J, Xie X, Wei Y. Expression of Wnt and Notch signaling pathways in inflammatory bowel disease treated with mesenchymal stem cell transplantation: evaluation in a rat model. Stem Cell Res Ther. 2015;6:101.
40. Hu CH, Tseng YW, Chiu CY, Lan KC, Chou CH, Tai CS, et al. Bone marrow concentrate-induced mesenchymal stem cell conditioned medium facilitates wound healing and prevents hypertrophic scar formation in a rabbit ear model. Stem Cell Res Ther. 2019;10:275.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.